NF-kB, a transcription factor, studied for an anticancer effect.

Published: 2000-05-02 16:17:00

Updated: 2000-05-02 16:17:00

A study report attracts many interests, covering that NF-kB, a transcription factor, may physiologically eradicate cancer cells, which suggested a possibility of utilizing it for a new cancer drug. The report was presented by Prof. Kim Kyung-mee, Wonkwang Univ. college of pharmacy during the symp...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK